SEC Info - AIkido Pharma Inc. - ‘8-K’ for 9/23/22

SEC Info℠

Home

Help

Please Sign In

AIkido Pharma Inc. – ‘8-K’ for 9/23/22

On: Thursday, 9/29/22, at 4:15pm ET · For: 9/23/22 · Accession #: 1213900-22-60201 · File #: 0-05576

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/29/22  AIkido Pharma Inc.                8-K:1       9/23/22   10:187K                                   EdgarAgents LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 5: R1          Cover                                               HTML     47K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- ea166546-8k_aikidopharma_htm        XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- aiki-20220923_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- aiki-20220923_pre              XML     63K 
 2: EX-101.SCH  XBRL Schema -- aiki-20220923                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
10: ZIP         XBRL Zipped Folder -- 0001213900-22-060201-xbrl      Zip     15K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0000012239 i false 0000012239 2022-09-23 2022-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i September 23, 2022

i AIKIDO PHARMA INC.

(Exact name of registrant as specified in its charter)

i Delaware		i 000-05576		i 52-0849320
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i One Rockefeller Plaza, i 11th Floor, i New York, i NY		i 10020
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: i (703) i 993-9325

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.0001 par value	i AIKI	The i Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01.

Entry Into a Material Definitive Agreement.

On September 23, 2022, Dominari Financial, Inc. (“Dominari”), a wholly owned subsidiary of AIkido Pharma, Inc, (the “Company”) entered into a Lease Agreement (the “Lease”) with Trump Tower Commercial LLC, a New York limited liability company.

Pursuant to the Lease, Dominari will rent a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari plans to use the Premises to run its day-to-day operations.

The initial term of the Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari.

Pursuant to the Lease, Dominari will pay rent equal to forty-nine thousand three hundred and sixty-eight dollars per month. Effective for the sixth and seventh years of the Lease, the rent shall increase to fifty-one thousand eight hundred and sixty-eight dollars per month.

The foregoing is a summary of the terms of the Lease, a copy of the Lease will be filed with the Company’s next Quarterly Report on Form 10-Q.

C: 1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 29, 2022	AIKIDO PHARMA INC.

	By:	/s/ *Anthony Hayes*
	Name:	Anthony Hayes
	Title:	Chief Executive Officer

Dates Referenced Herein

This ‘8-K’ Filing	Date	Other Filings

Filed on:	9/29/22	None on these Dates
For Period end:	9/23/22
		List all Filings

↑Top

Filing Submission 0001213900-22-060201 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)